Products & Services

Epidemiology-Focused Products & Services

Epidemiology forecast models and insights built for the pharmaceutical industry and allied organizations.

Core Product

G26 Epidemiology Forecast

Epidemiology forecast models for non-oncology indications

In-depth, rigorously researched epidemiology forecast models covering 26 high-income countries* (including China). Available as interactive downloadable Excel dashboards with accompanying PDF study report.

Features
20-year forecast period Commercial alignment 150 drug-indications target coverage 26-country coverage Disease burden outcomes Interactive patient funnel/flow diagrams Regular model updates

“*Australia, Austria, Belgium, Canada, China, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, UK, USA.

G26 Epidemiology Forecast

All our G26 Epidemiology Forecast Models have one or more interactive patient funnel or patient flow diagrams which can be exported as image files and displayed for any combination of country and forecast year. In our partner program, epidemiologist hours can be used to add/remove patient populations and derive patient funnels from a different perspective.

CORE PRODUCT

G26 Oncology Forecast

Epidemiology forecast models for oncology indications

In-depth, rigorously researched cancer epidemiology forecast models covering 26 high-income countries* (including China). Available as interactive downloadable Excel dashboards with accompanying PDF study report.

Features
20-year forecast period Commercial alignment 50 tumors target coverage 26-country coverage Detailed tumor genetics Interactive patient flow diagrams Race/ethnicity-based forecast (USA) Regular model updates

* Australia, Austria, Belgium, Canada, China, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, UK, USA.

G26 Oncology Forecast

All our G26 Oncology Forecast Models have interactive patient flow diagrams which can be exported as image files and displayed for any combination of country and forecast year. In our partner program, epidemiologist hours can be used to derive patient flows for specific biomarker, mutation or alternative staging system populations.

CORE PRODUCT

Cancer Populations USA

Deep-dive long range customizable USA forecast models

Customizable race/ethnicity-based forecasts of cancer populations in the USA, stratified by race/ethnicity, state, tumor mutation status, biomarkers and line of treatment. Available as interactive downloadable Excel dashboards with accompanying PDF study report.

Features
20-year forecast period Full driver/druggable mutations Race-ethnicity breakdown State-specific estimates Interactive patient flow diagrams
Cancer Populations USA

All our Cancer Populations USA reports are built from base year estimates of differential risk between different race-ethnicity groups and stratify first-line drug-treatable populations by a full panel of driver or potentially/actually druggable gene mutations.

Bespoke service

Rare Disease Epidemiology Service

Custom-built epidemiology models of rare disease and niche indications

With our expertise in the modelling of rare disease epidemiology data, our familiarity with relevant datasets and the design of RWE studies in rare diseases, we can deliver rigorously researched, transparent interactive epidemiology forecast models. See our case studies from some recent examples.

Features
Newborn screening program-based models time-to-event modeling incidence-to-prevalence models state-transition modeling rare disease epidemiology SLRs Hybrid SLR-PMR parameter estimation
Rare Disease Epidemiology Service

Using published newborn screening data for rare congenital disease, using our time-to-event and survival modeling approach, we can estimate multiple incident and prevalent populations following any initial newborn diagnosis, and add in the pre-existing populations not identified with newborn screening.

Ready To Access Premium Research?

Request Access Today And Our Team Will Set You Up Within 2 Business Days.